Pharma/Biotech Deal Pipeline, 7/21-25/08
A quick recap of major deals in the week that was, with a big hat tip to the In Vivo Blog:
- Obviously, the big kahuna of the week was Roche’s $43.7 billion bid for Genentech. But Roche wasn’t close to finished: The Swiss drugmaker also paid C$191 million ($189.3 million) for the Canadian biotech Arius Research, a developer of antibody-screening systems, and $125 million for Mirus Bio, a Wisconsin biotech with a proprietary RNA-interference technology. The Mirus deal also marks Roche’s second foray into RNAi in the past year.
- Sanofi-Aventis offered £276 million ($548.4 million) to acquire vaccine-maker Acambis, with whom Sanofi has been working for roughly a decade.
- BioMarin Pharmaceutical agreed to pay $7 million upfront and up to $136 million in possible milestone and royalty payments to Summit for a drug intended to fight muscular dystrophy.
- GlaxoSmithKline struck a deal with South Africa’s Aspen to break into the generic-drug market across the developing world.
Image via Flickr user mobilestreetlife, CC 2.0
A 14-year veteran of the Wall Street Journal, David P. Hamilton is BNET's Industries editor. Prior to coming to BNET, David founded the LifeScience section of VentureBeat, a news site for the innovation and venture business.
BNET User Analysis